Free Trial
→ A little-known law has been quietly applied to your savings for years. (From Monetary Gold) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
$0.00
▼
$0.00
$2K1.347,613 shs25 shs
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$0.00
$0.00
▼
$0.00
$6K1.6183,499 shsN/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
$0.00
$0.00
$0.00
▼
$0.02
$8K-0.994,250 shs569 shs
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
$0.00
$0.00
$0.00
▼
$0.00
$7K-0.275,393 shsN/A
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00%0.00%-50.00%0.00%-80.00%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00%0.00%0.00%0.00%0.00%
PaxMedica, Inc. stock logo
PXMD
PaxMedica
0.00%0.00%0.00%+40.00%+600.00%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00%0.00%0.00%+300.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
$0.00
▼
$0.00
$2K1.347,613 shs25 shs
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$0.00
$0.00
▼
$0.00
$6K1.6183,499 shsN/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
$0.00
$0.00
$0.00
▼
$0.02
$8K-0.994,250 shs569 shs
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
$0.00
$0.00
$0.00
▼
$0.00
$7K-0.275,393 shsN/A
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00%0.00%-50.00%0.00%-80.00%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00%0.00%0.00%0.00%0.00%
PaxMedica, Inc. stock logo
PXMD
PaxMedica
0.00%0.00%0.00%+40.00%+600.00%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00%0.00%0.00%+300.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00
N/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00
N/AN/AN/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
0.00
N/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$1.91M0.00N/AN/A$0.47 per share0.00
PaxMedica, Inc. stock logo
PXMD
PaxMedica
N/AN/AN/AN/A$0.46 per shareN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-$114.53M-$0.66N/AN/AN/AN/AN/AN/A11/17/2026 (Estimated)
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
-$18.29M-$6.09N/AN/AN/AN/A-3,167.89%-560.35%12/2/2026 (Estimated)
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
-$11.61MN/AN/AN/AN/AN/AN/AN/A12/2/2026 (Estimated)

Latest EVLO, PXMD, SCPS, and GNCA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
12/2/2026N/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
-$0.88N/AN/AN/AN/AN/A
12/2/2026N/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
-$0.22N/AN/AN/AN/AN/A
11/17/2026N/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-$10.1333N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
N/AN/AN/AN/AN/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
N/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.24
1.35
1.35
PaxMedica, Inc. stock logo
PXMD
PaxMedica
N/A
0.38
0.38
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.31%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.64%
PaxMedica, Inc. stock logo
PXMD
PaxMedica
4.90%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/A

Insider Ownership

CompanyInsider Ownership
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
1.02%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
1.61%
PaxMedica, Inc. stock logo
PXMD
PaxMedica
1.00%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
5.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
12018.84 million18.79 millionNo Data
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
7058.73 million57.79 millionNot Optionable
PaxMedica, Inc. stock logo
PXMD
PaxMedica
611.31 million11.20 millionNot Optionable
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
918.09 million39.94 millionNot Optionable

Recent News About These Companies

Scopus BioPharma's Subsidiary - Duet BioTherapeutics - Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for ...
June 25, 2026  |  stockhouse.comhttps://stockhouse.com/news/press-releases/2023/11/07/scopus-biopharma-s-subsidiary-duet-biotherapeutics-presents-compelling-new-data
Scopus Stock Price History
June 10, 2026  |  investing.comhttps://www.investing.com/equities/scopus-biopharma-inc-historical-data
SCPS Scopus BioPharma Inc.
May 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/SCPS
Scopus Stock Price History - Investing.com
June 29, 2025  |  investing.comhttps://www.investing.com/equities/scopus-biopharma-inc-historical-data?_pmch=1701365167553
Scopus Biopharma Inc (SCPS) Stock Forums - Investing.com
June 29, 2025  |  investing.comhttps://www.investing.com/equities/scopus-biopharma-inc-commentary
Scopus Biopharma Inc Price / Book
November 26, 2024  |  investing.comhttps://www.investing.com/pro/OTCPK:SCPS/explorer/price_to_book
Scopus BioPharma (OTC:SCPS) Stock, Short Interest Report
October 8, 2024  |  benzinga.comhttps://www.benzinga.com/quote/SCPS/short-interest
Scopus Biopharma Inc (SCPS)
February 14, 2024  |  uk.investing.comhttps://uk.investing.com/equities/scopus-biopharma-inc
ArriVent BioPharma Inc AVBP
February 6, 2024  |  morningstar.comM
Scopus BioPharma Inc. (SCPS)
January 31, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/quote/SCPS/history/
7+ Companies That Had Their IPO in 2020: Best and Worst Performers
January 8, 2024  |  msn.comhttps://www.msn.com/en-us/money/markets/7-companies-that-had-their-ipo-in-2020-best-and-worst-performers/ss-AA1mylo0
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer
November 7, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/scopus-biopharma-subsidiary-duet-biotherapeutics-141500851.html?.tsrc=rss
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
November 2, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/scopus-biopharma-subsidiary-duet-biotherapeutics-131500358.html
Kinnate Biopharma Inc Ordinary Shares
July 15, 2023  |  morningstar.comM
This Biopharma Offspring Is All Grown Up
May 23, 2023  |  mddionline.comM
Scopus BioPharma Stock (OTC:SCPS), Insider Trading Activity
May 16, 2023  |  benzinga.comhttps://www.benzinga.com/quote/SCPS/insider-trades
ESG Industry Landscape Report: Biopharma
April 19, 2023  |  morningstar.comM
These are the roles biopharma companies want to fill
April 9, 2023  |  siliconrepublic.comS
YS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQ
March 18, 2023  |  benzinga.comhttps://www.benzinga.com/pressreleases/23/03/n31388860/ys-biopharma-to-ring-the-opening-bell-and-debut-on-nasdaq
Short Volatility Alert: Scopus Biopharma I
December 16, 2022  |  benzinga.comhttps://www.benzinga.com/markets/penny-stocks/22/12/30112384/short-volatility-alert-scopus-biopharma-i
Evelo Biosciences stock logo

Evelo Biosciences NASDAQ:EVLO

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Genocea Biosciences stock logo

Genocea Biosciences NASDAQ:GNCA

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

PaxMedica stock logo

PaxMedica NASDAQ:PXMD

$0.0007 0.00 (0.00%)
As of 11/11/2026 09:30 AM Eastern

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

Scopus BioPharma stock logo

Scopus BioPharma NASDAQ:SCPS

$0.0004 0.00 (0.00%)
As of 11/11/2026

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas